$VKTX.US is Viking Therapeutics, a clinical-stage biopharmaceutical company, not a cryptocurrency.
Its main program, VK2735, is being developed for obesity and is currently in Phase 3 studies.
On September 22, 2026, the company reported positive results from a VK2735 maintenance study.
VKTX’s share price rose sharply that day, closing at $40.85, up 35.67%.
Because it is a clinical-stage biotech, future performance can depend heavily on trial results and regulatory developments.
#AIStocksWhatNext #DogecoinRises15% #BNBMarketCapPassesBNYMellon #MuseOvertakesChatGPTAsTopFreeIOSApp
Its main program, VK2735, is being developed for obesity and is currently in Phase 3 studies.
On September 22, 2026, the company reported positive results from a VK2735 maintenance study.
VKTX’s share price rose sharply that day, closing at $40.85, up 35.67%.
Because it is a clinical-stage biotech, future performance can depend heavily on trial results and regulatory developments.
#AIStocksWhatNext #DogecoinRises15% #BNBMarketCapPassesBNYMellon #MuseOvertakesChatGPTAsTopFreeIOSApp
